VA Disability for Chronic Urticaria: DC 7825 Rating Explained (2026)

What DC 7825 Covers

Diagnostic Code 7825 in 38 CFR 4.118 is the VA's rating code for chronic urticaria. Chronic urticaria is defined clinically as urticaria (hives, or wheals) that persists for six weeks or longer or recurs intermittently over that period. The condition is divided into chronic spontaneous urticaria (CSU), in which the hives appear without an identifiable trigger, and chronic inducible urticaria (CIU), in which the hives reliably appear in response to a specific stimulus (pressure, cold, heat, sunlight, water, vibration, exercise, or cholinergic stimuli).

The rating schedule was substantively revised in 2018 and now turns on episode frequency and the intensity of treatment required for control, rather than on the appearance or area of the lesions themselves. The treatment-intensity framework recognizes that severity is best captured by what therapy is needed, not by the visible lesion burden at a single examination.

Chronic Urticaria: The Underlying Pathology

The wheal of urticaria results from histamine and other mediator release from cutaneous mast cells. The released mediators produce vasodilation, increased vascular permeability, and dermal edema, producing the characteristic raised, blanching, intensely itchy lesion. The wheal typically resolves within 24 hours of its onset and migrates to new locations over the course of a flare.

Chronic Spontaneous Urticaria

CSU is mediated by mast cell activation in the absence of an identifiable external trigger. The current understanding emphasizes autoimmune mechanisms (anti-IgE or anti-FcεRI autoantibodies in a subset of patients) and chronic low-grade activation of mast cells through various intrinsic pathways. CSU is associated with a higher prevalence of autoimmune disease including autoimmune thyroiditis and connective tissue diseases.

Chronic Inducible Urticaria

CIU subtypes include dermographism (pressure-induced wheals after stroking), cold urticaria, cholinergic urticaria (heat or exercise-induced), solar urticaria, aquagenic urticaria, and vibratory urticaria. Each has a distinct provocation test that establishes the diagnosis.

Angioedema

Up to 40 percent of chronic urticaria patients also experience angioedema, the deeper dermal and subcutaneous swelling that produces lip, periorbital, or extremity puffiness. Angioedema with airway compromise is a medical emergency, and the history of any such episode is significant.

Service-Related Triggers

Service-related factors potentially contributing to chronic urticaria include exposure to particulate matter (burn pit, sand and dust), chemical exposures (jet fuel, organic solvents), insect repellents, and antimalarial or other deployment medications. Service-related stress and PTSD may also be associated with mast cell hyperreactivity through the brain-skin axis, though this association remains under active investigation.

The Rating Tiers in Detail

DC 7825 provides three tiers, all requiring at least four recurrent episodes in the past 12-month period.

10 Percent

Recurrent episodes occurring at least four times during the past 12-month period and responding to treatment with antihistamines or sympathomimetics. This tier captures veterans whose condition is well-controlled with second-generation H1 antihistamines (cetirizine, fexofenadine, loratadine, levocetirizine) or with as-needed sympathomimetic therapy.

30 Percent

Recurrent debilitating episodes occurring at least four times during the past 12-month period and requiring intermittent systemic immunosuppressive therapy for control. The "intermittent systemic immunosuppressive therapy" language captures veterans who require courses of oral corticosteroids (prednisone), cyclosporine, methotrexate, or other immunomodulators on a flare-by-flare or short-cycle basis.

The term "debilitating" requires more than mild itch; the record should describe interference with sleep, work, or daily activities during episodes.

60 Percent

Recurrent debilitating episodes occurring at least four times during the past 12-month period despite continuous immunosuppressive therapy. The "continuous" requirement distinguishes this tier from the 30 percent tier; veterans on ongoing therapy with omalizumab (Xolair) monthly injections, daily cyclosporine, or maintenance oral immunosuppressive therapy who still flare four or more times per year fall in this tier.

Angioedema as an Independent Manifestation

Recurrent angioedema can be rated separately under DC 7118 (angioneurotic edema) when its manifestations are distinct from the urticaria. The rater must avoid pyramiding under 38 CFR 4.14, so the angioedema rating should capture distinct functional impairment (swelling, airway compromise, attack frequency) beyond what is already captured under DC 7825.

Service Connection Pathways

Several pathways are available for chronic urticaria.

Direct Service Connection

When service treatment records document urticaria during service, within a year of separation, or trace a clear continuity of symptoms from in-service onset, direct service connection is the most straightforward pathway. A medical nexus opinion may not be required when the in-service documentation is sufficient.

Secondary Service Connection Under 38 CFR 3.310

Chronic urticaria can be secondary to:

• Service-connected autoimmune thyroid disease (the autoimmune CSU subtype)
• Service-connected lupus, vasculitis, or other connective tissue disease
• Medications used to treat a service-connected condition (NSAID-induced or ACE-inhibitor-induced urticaria, although the latter is more commonly angioedema)
• Service-connected stress disorders through neuroimmune mast cell activation (an emerging but less well-established mechanism)

Aggravation Theory

When chronic urticaria predated military service or arose from another cause but was aggravated by service exposures or by a service-connected condition, the aggravation pathway under 38 CFR 3.310(b) requires the opinion to identify baseline versus current severity.

The Gulf War Presumptive Path

38 CFR 3.317 provides for presumptive service connection of certain medically unexplained chronic multisymptom illnesses and qualifying chronic disabilities for veterans who served in the Southwest Asia Theater of Operations. Skin manifestations including chronic urticaria can be evaluated under the presumptive framework in some presentations, particularly when no alternative explanation is identified after appropriate workup.

The presumptive pathway requires only a qualifying period of service, a current diagnosis manifesting to a degree of 10 percent or more, and the absence of an alternative explanation. It does not require a nexus opinion. The presumptive theory and the direct or secondary theories can be argued in the alternative.

Evidence That Supports the Rating

The records most useful for a defensible DC 7825 rating include the following.

Specialist Evaluation

Allergist or dermatologist evaluation establishing the diagnosis (CSU or CIU subtype), documenting the duration of symptoms, and recording any provocation testing for inducible subtypes. The evaluation should reference the Urticaria Activity Score over 7 days (UAS7) or the Urticaria Control Test (UCT) when available.

Flare Diary

A patient-maintained flare diary documenting episode frequency, duration, severity, body areas involved, triggers, and treatment used over at least three months is among the most useful evidence for the frequency-based schedule.

Photographs

Time-stamped photographs of typical lesions taken at the time of a flare, particularly because examination at a clinic visit is often unremarkable.

Treatment History

Detailed pharmacy and clinical records of antihistamine doses (including up-dosing to 2x or 4x label dose, which is the European Academy of Allergy and Clinical Immunology guideline approach), omalizumab injection schedule, cyclosporine or other immunosuppressant prescriptions, oral steroid bursts, and any documented refractoriness or partial response.

Functional Impact

Statements from the veteran, family members, and supervisors describing sleep disturbance from nocturnal itch, work absenteeism during flares, social withdrawal due to visible lesions, and daily activities affected by the condition.

Common Pitfalls

Several recurring issues weaken chronic urticaria claims.

Examination-Only Documentation

When a C&P examination occurs between flares, the unremarkable skin examination can be misinterpreted as inactive disease. The veteran and the medical opinion should emphasize that chronic urticaria is intermittent by definition and that the rating turns on the prior 12-month frequency and treatment intensity, not the appearance on examination day.

Missing Frequency Documentation

The 10, 30, and 60 percent tiers all require at least four episodes in the past 12 months. Without a flare diary or itemized clinical records, the frequency element may be doubted. The diary is among the most powerful evidentiary tools available.

Confusing 30 Percent and 60 Percent Tiers

The distinction is "intermittent" versus "continuous" immunosuppression. A veteran on monthly omalizumab who still flares meets the 60 percent threshold; a veteran on intermittent prednisone bursts for flares meets the 30 percent threshold.

Failure to Address Alternative Diagnoses

When the workup has not excluded urticarial vasculitis (lesions lasting longer than 24 hours, post-inflammatory hyperpigmentation), bullous pemphigoid pre-bullous phase, or other urticarial-mimicking conditions, the diagnosis may be challenged. Strong records include or recommend skin biopsy when atypical features are present.